EGF-dependent induction of BCL-xL and p21CIP1/WAF1 is highly variable in HNSCC cells - Implications for EGFR-targeted therapies

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4579-4585

  Jessica, Rüddel ^a   Wennekes, Vanessa E ^a   Wolfgang, Meissner ^b   Werner, Jochen A ^a   Mandic, Robert ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

L; BCL x; EGF; EGFR; HNSCC; p21CIP1 WAF1

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN BCL XL;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; HEAD AND NECK CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; WESTERN BLOTTING;

BCL-X PROTEIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 78650278294     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ferlito A, Rinaldo A, Silver CE and Shaha AR: The head and neck surgeon as oncologist. Am J Otolaryngol 27: 73-75, 2006.
2. Hall MD, Okabe M, Shen DW, Liang XJ and Gottesman MM: The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535, 2008.
3. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressier LG, Shores CG, Yarbrough WG and Perou CM: Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500, 2004. (Pubitemid 38610250)
4. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
5. Pena JC, Thompson CB, Recant W, Vokes EE and Rudin CM: Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 85: 164-170, 1999.
6. Fischer OM, Hart S, Gschwind A and Ullrich A: EGFR signal transactivation in cancer cells. Biochem Soc Trans 31: 1203-1208, 2003.
7. (Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 3: 1943-1948, 1997.
8. Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. Anticancer Res 20: 103-111, 2000.
9. Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol 131: 235-242, 1995.
10. van den Broek GB, Wildeman M, Rasch CR, Armstrong N, Schuuring E, Begg AC, Looijenga LH, Scheper R, van der Wal JE, Menkema L, van Diest PJ, Balm AJ, van Velthuysen ML and van den Brekel MW: Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer 124: 2643-2650, 2009.
11. Song JI and Grandis JR: STAT signaling in head and neck cancer. Oncogene 19: 2489-2495, 2000.
12. (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 74: 383-389, 1997.
13. Rodeck U, Jost M, DuHadaway J, Kari C, Jensen PJ, Risse B and Ewert DL: Regulation of Bcl-xL expression in human keratinocytes by cell-substratum adhesion and the epidermal growth factor receptor. Proc Natl Acad Sci USA 94: 5067-5072, 1997.
14. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL and Jensen PJ: EGF-R dependent regulation of keratinocyte survival. J Cell Sci 110(Pt 2): 113-121, 1997.
15. L expression through a MEK-dependent pathway. J Biol Chem 276: 6320-6326, 2001.
16. Mandic R, Eikelkamp N, Peldszus R, Sadowski M, Sesterhenn AM, Dunne AA and Werner JA: Variations of EGF-R surface expression in squamous cell carcinomas of the head and neck region. Anticancer Res 21: 3413-3418, 2001.
17. Mandic R, Schamberger CJ, Muller JF, Geyer M, Zhu L, Carey TE, Grenman R, Dunne AA and Werner JA: Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 11: 6845-6852, 2005.
18. Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E, Neubauer A and Werner JA: Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 580: 4793-4800, 2006.
19. Bauer JA, Kumar B, Cordell KG, Prince ME, Tran HH, Wolf GT, Chepeha DB, Teknos TN, Wang S, Eisbruch A, Tsien CI, Urba SG, Worden FP, Lee J, Griffith KA, Taylor JM, D'Silva N, Wang SJ, Wolter KG, Henson B, Fisher SG, Carey TE and Bradford CR: Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys 69: S106-S108, 2007.
20. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, Chen J, Wang S, Bradford CR and Carey TE: Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther 4: 1096-1104, 2005.
21. (L) in the regulation of keratinocyte survival by autocrine EGFR ligands. J Invest Dermatol 112: 443-449, 1999.
22. (L) expression. J Invest Dermatol 116: 860-866, 2001.
23. Gartel AL and Radhakrishnan SK: Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980-3985, 2005.
24. Mandic R, Rodgarkia-Dara CJ, Krohn V, Wiegand S, Grenman R and Werner JA: Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF receptor. Anticancer Res 29: 1181-1188, 2009.